An examination by The New York Times and The Observer of London reveals how Cambridge Analytica's drive to bring to market
a potentially powerful new weapon put the firm — and wealthy conservative investors seeking to reshape politics — under scrutiny from investigators and lawmakers on both sides of the Atlantic.